AR061994A1 - Uso de derivados de imidazol activadores de ampk, su proceso de preparacion y composiciones farmaceuticas que los comprenden - Google Patents
Uso de derivados de imidazol activadores de ampk, su proceso de preparacion y composiciones farmaceuticas que los comprendenInfo
- Publication number
- AR061994A1 AR061994A1 ARP070103120A ARP070103120A AR061994A1 AR 061994 A1 AR061994 A1 AR 061994A1 AR P070103120 A ARP070103120 A AR P070103120A AR P070103120 A ARP070103120 A AR P070103120A AR 061994 A1 AR061994 A1 AR 061994A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- aryl
- optionally substituted
- groups
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 3
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 title abstract 2
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 1
- 230000003213 activating effect Effects 0.000 title 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 10
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 8
- -1 amino, hydroxyl Chemical group 0.000 abstract 8
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 150000002367 halogens Chemical class 0.000 abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 abstract 6
- 125000005915 C6-C14 aryl group Chemical group 0.000 abstract 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 abstract 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Chemical group 0.000 abstract 2
- 229910052717 sulfur Chemical group 0.000 abstract 2
- 239000011593 sulfur Chemical group 0.000 abstract 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000012190 activator Substances 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 150000002460 imidazoles Chemical class 0.000 abstract 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 150000003568 thioethers Chemical class 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Child & Adolescent Psychology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se refiere al uso de derivados de imidazol de la fórmula (1), donde: A representa -NH- u -O-; R¹ está seleccionado de: alquilo C₁₋₈ lineal o ramificado, opcionalmente sustituido con uno o varios grupos que pueden ser iguales o diferentes, seleccionados de cicloalquilo, alcoxi, carboxilo y alquilcarbonilo; arilo C₆₋₁₄ opcionalmente sustituido con une o varios grupos Y, que pueden ser iguales o diferentes; -aril C₆₋₁₄-alquilo C₁₋₈, estando el grupo arilo opcionalmente sustituido con uno o varios grupos Y, que pueden ser iguales o diferentes; aril C₆₋₁₄-oxi-alquilo C₁₋₈, estando el grupo arilo opcionalmente sustituido con uno o varios grupos Y, que pueden ser iguales o diferentes; heteroarilo C₆₋₁₄, heteroaril C₆₋₁₄-alquilo C₁₋₈, heteroaril C₆₋₁₄-oxi-alquilo C₁₋₈, estando el grupo heteroarilo de cada uno de estos grupos en sí opcionalmente sustituido con uno o varios grupos Y, que pueden ser iguales o diferentes, entendiéndose que dicho grupo heteroarilo puede contener uno o varios heteroátomos seleccionados de nitrógeno, oxigeno y azufre; R² está seleccionado de: hidrógeno; alquilo C₁₋₈ lineal o ramificado, opcionalmente sustituido con uno o varios grupos que pueden ser iguales o diferentes, seleccionados de cicloalquilo, alcoxi, carboxilo y alquilcarbonilo; cicloalquilo C₃₋₁₀ opcionalmente sustituido con uno o varios grupos que pueden ser iguales o diferentes, seleccionados de cicloalquilo, alcoxi, carboxilo y alquilcarbonilo; aril C₆₋₁₄-alquilo C₁₋₈, estando el grupo arilo opcionalmente sustituido con uno o varios grupos seleccionados, de modo independiente, de amino, hidroxilo, ciano, tio, halógeno, alquilo C₁₋₈, alcoxi C₁₋₈, alquil C₁₋₈-tio, alquil C₁₋₈-amino, arilo C₆₋₁₄, aril C₆₋₁₄-oxi, aril C₆₋₁₄-alcoxi C₁₋₈ e Y; acilo C₂₋₁₄, opcionalmente sustituido con uno o varios grupos seleccionados, de modo independiente, de amino, hidroxilo, ciano, tio, halógeno, alquilo C₁₋₈, alcoxi C₁₋₈, alquil C₁₋₈-tio, alquil C₁₋₈-amino, arilo C₆₋₁₄, aril C₆₋₁₄-oxi, aril C₆₋₁₄-alcoxi C₁₋₈ e Y; y R³ representa hidrógeno o alquilo C₁₋₈ lineal o ramificado, opcionalmente sustituido con uno o varios grupos que pueden ser iguales o diferentes, seleccionados de cicloalquilo, alcoxi, carboxilo y alquilcarbonilo; Y está seleccionado de hidrógeno, amino, nitro, hidroxilo, ciano, tio, halógeno, alquilo C₁₋₈, alcoxi C₁₋₈, alcoxi C₁₋₈-carbonilo, alquil C₁₋₈-tio, alquil C₁₋₈-amino, arilo C₆₋₁₄, aril C₆₋₁₄-oxi y aril C₆₋₁₄-alcoxi C₁₋₈, o un resto del grupo de fórmulas (2) en donde T está seleccionado de: alquilo C₁₋₈ lineal o ramificado, opcionalmente sustituido; cicloalquilo C₃₋₁₀ opcionalmente sustituido; arilo C₆₋₁₄ opcionalmente sustituido con uno o varios grupos seleccionados, de modo independiente, de halógeno, ciano, alcoxi C₁₋₈, cicloalquil C₃₋₈-alquilo C₁₋₈, alcoxi C₁₋₈-carbonilo, hidroxicarbonilo y alquil C₁₋₈-tio; aril C₆₋₁₄-alquilo C₁₋₈, estando el grupo arilo opcionalmente sustituido con uno o varios grupos seleccionados, de modo independiente, de halógeno, ciano, alcoxi C₁₋₈, cicloalquil C₃₋₁₀-alquilo C₁₋₈, alcoxi C₁₋₈-carbonilo, hidroxicarbonilo y alquil C₁₋₈-tio; heteroarilo C₆₋₁₄, heteroaril C₆₋₁₄-alquilo C₁₋₈, heteroaril C₆₋₁₄-oxi-alquilo C₁₋₈, estando el grupo heteroarilo de cada uno de estos grupos en si posiblemente sustituido con uno o varios grupos seleccionados, de modo independiente, de halógeno, alcoxi C₁₋₈, cicloalquil C₃₋₈-alquilo C₁₋₈, alcoxi C₁₋₈-carbonilo, hidroxicarbonilo y alquil C₁₋₈-tio; entendiéndose que dicho grupo heteroarilo puede contener uno o varios heteroátomos seleccionados de nitrógeno, oxígeno y azufre; y de sus posibles isómeros geométricos y/u ópticos, epímeros y formas tautoméricas, y formas oxidadas posibles, en especial óxidos de amina, tioéteres e hidratos, y también sus posibles sales por adición con un ácido o base farmacéuticamente aceptable, o los profármacos farmacéuticamente aceptables de estos compuestos. Como activadores de AMPK. También se refiere a procesos para la preparación de dichos compuestos, a sus usos para la preparación de medicamentos para el tratamiento de insulinorresistencia, diabetes y patologías relacionadas, y también obesidad, y a las composiciones farmacéuticas que los comprenden. Ciertos compuestos de la fórmula (1) son nuevos y, en este sentido, también forman parte de la presente.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0606415A FR2903695B1 (fr) | 2006-07-13 | 2006-07-13 | Utilisation de derives d'imidazole activateurs de l'ampk, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR061994A1 true AR061994A1 (es) | 2008-08-10 |
Family
ID=37696444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070103120A AR061994A1 (es) | 2006-07-13 | 2007-07-13 | Uso de derivados de imidazol activadores de ampk, su proceso de preparacion y composiciones farmaceuticas que los comprenden |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8329738B2 (es) |
| EP (1) | EP2040702B1 (es) |
| JP (1) | JP5237941B2 (es) |
| AR (1) | AR061994A1 (es) |
| AT (1) | ATE517621T1 (es) |
| AU (1) | AU2007272082B2 (es) |
| CA (1) | CA2657335C (es) |
| DK (1) | DK2040702T3 (es) |
| ES (1) | ES2367852T3 (es) |
| FR (1) | FR2903695B1 (es) |
| IL (1) | IL196280A (es) |
| PL (1) | PL2040702T3 (es) |
| PT (1) | PT2040702E (es) |
| WO (1) | WO2008006432A1 (es) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| HRP20131069T1 (hr) * | 2008-06-16 | 2013-12-20 | Merck Patent Gmbh | Derivati kinoksalindiona |
| FR2933694B1 (fr) * | 2008-07-10 | 2016-10-21 | Oreal | Utilisation de phenoxyalkylamines dans des compositions cosmetiques et/ou dermatologiques. |
| WO2010036613A1 (en) | 2008-09-26 | 2010-04-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| CA2741125A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| JP2013047189A (ja) * | 2009-12-25 | 2013-03-07 | Kyorin Pharmaceutical Co Ltd | 新規パラバン酸誘導体及びそれらを有効成分とする医薬 |
| US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2552435A1 (en) * | 2010-04-02 | 2013-02-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions comprising ampk activator (metformin/troglitazone) for the treatment of myotonic dystrophy type 1 (dm1) |
| WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| JP2013230986A (ja) * | 2010-08-25 | 2013-11-14 | Kyorin Pharmaceutical Co Ltd | 新規ヒダントイン誘導体及びそれらを有効成分とする医薬 |
| JP2013537240A (ja) | 2010-09-20 | 2013-09-30 | カリウス セラピューティクス エスエー | 糖尿病および脂質異常症の処置のための方法および組成物 |
| US9005909B2 (en) | 2011-01-06 | 2015-04-14 | Rigel Pharmaceuticals, Inc. | Whole blood assay for measuring AMPK activation |
| BR112013021236B1 (pt) | 2011-02-25 | 2021-05-25 | Merck Sharp & Dohme Corp | composto derivado de benzimidazol, e, composição |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| PL223830B1 (pl) | 2012-04-03 | 2016-11-30 | Univ Jagiellonski | Pochodne aromatycznych imidazolidynonów i ich zastosowanie |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| EP2888008B1 (en) | 2012-08-22 | 2018-12-26 | Merck Sharp & Dohme Corp. | Novel azabenzimidazole tetrahydrofuran derivatives |
| JP2015526468A (ja) | 2012-08-22 | 2015-09-10 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 新規なアザベンズイミダゾールヘキサヒドロフロ［３，２−ｂ］フラン誘導体 |
| US9527839B2 (en) | 2012-08-22 | 2016-12-27 | Merck Sharp & Dohme Corp. | Benzimidazole tetrahydropyran derivatives |
| WO2014031441A1 (en) | 2012-08-22 | 2014-02-27 | Merck Sharp & Dohme Corp. | Novel benzimidazole tetrahydrofuran derivatives |
| US9382243B2 (en) | 2012-08-22 | 2016-07-05 | Merck Sharp & Dohme Corp. | Azabenzimidazole tetrahydropyran derivatives |
| US9556193B2 (en) | 2012-08-22 | 2017-01-31 | Merck Shapr & Dohme Corp. | Benzimidazole hexahydrofuro[3,2-b]furan derivatives |
| RS56032B1 (sr) * | 2013-01-15 | 2017-09-29 | Fujifilm Corp | Tableta koja sadrži 5-hidroksi-1h-imidazol-4-karboksamid |
| US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
| CA2905242C (en) | 2013-03-15 | 2016-11-29 | Pfizer Inc. | Indole compounds that activate ampk |
| EP3089748A4 (en) | 2014-01-02 | 2017-09-27 | Massachusetts Eye & Ear Infirmary | Treating ocular neovascularization |
| EP3355876A2 (en) | 2015-09-30 | 2018-08-08 | Instituto de Medicina Molecular | Methods for attenuating parasite virulence |
| CN108689939A (zh) | 2017-04-07 | 2018-10-23 | 厦门华绰生物医药科技有限公司 | 取代咪唑盐类化合物、其制备方法、药用组合物及其应用 |
| KR20230012597A (ko) | 2020-05-19 | 2023-01-26 | 칼리오페, 인크. | Ampk 활성화제 |
| AU2021297323A1 (en) | 2020-06-26 | 2023-02-16 | Kallyope, Inc. | AMPK activators |
| EP4221700A1 (en) | 2020-09-30 | 2023-08-09 | Bioverativ Therapeutics Inc. | Ampk activators and methods of use thereof |
| WO2022106892A1 (en) | 2020-11-17 | 2022-05-27 | Instituto De Medicina Molecular | Anti-malarial compounds |
| CA3238252A1 (en) | 2021-11-19 | 2023-05-25 | Amit Choudhary | Bifunctional chimeric molecules for labeling of kinases with target binding moieties and methods of use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4140788A (en) | 1976-11-10 | 1979-02-20 | Sumitomo Chemical Company, Limited | N-Substituted imidazolecarboxamide derivatives |
| JPS5379778A (en) | 1976-12-24 | 1978-07-14 | Shimizu Construction Co Ltd | Manufacture of mat made of granule |
| JPS5748971A (en) * | 1980-09-08 | 1982-03-20 | Sumitomo Chem Co Ltd | Novel alkylimidazole derivative |
| US6482844B1 (en) * | 2000-04-07 | 2002-11-19 | Neurogen Corporation | 1-benzylimidazole derivatives |
| WO2002009726A1 (en) | 2000-07-31 | 2002-02-07 | Trustees Of Boston University | Methods of treating conditions associated with insulin resistance with aicar, (5-amino-4-imidazole carboxamide riboside) and related compounds |
| DE10150172A1 (de) * | 2001-10-11 | 2003-04-30 | Morphochem Ag | Neue Verbindungen, die Protein Tyrosin Phosphatase 1B (PTP-1B) inhibieren |
| FR2846656B1 (fr) | 2002-11-05 | 2004-12-24 | Servier Lab | Nouveaux derives d'imidazopyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US7119205B2 (en) | 2003-05-16 | 2006-10-10 | Abbott Laboratories | Thienopyridones as AMPK activators for the treatment of diabetes and obesity |
| JP2005089384A (ja) | 2003-09-18 | 2005-04-07 | Kao Corp | 持久力向上剤 |
| JP5339664B2 (ja) | 2004-02-13 | 2013-11-13 | 花王株式会社 | Ａｍｐｋ活性化剤 |
-
2006
- 2006-07-13 FR FR0606415A patent/FR2903695B1/fr not_active Expired - Fee Related
-
2007
- 2007-06-12 US US12/373,310 patent/US8329738B2/en not_active Expired - Fee Related
- 2007-06-12 WO PCT/EP2007/005164 patent/WO2008006432A1/en not_active Ceased
- 2007-06-12 EP EP07725977A patent/EP2040702B1/en active Active
- 2007-06-12 JP JP2009518732A patent/JP5237941B2/ja not_active Expired - Fee Related
- 2007-06-12 ES ES07725977T patent/ES2367852T3/es active Active
- 2007-06-12 AU AU2007272082A patent/AU2007272082B2/en not_active Ceased
- 2007-06-12 DK DK07725977.8T patent/DK2040702T3/da active
- 2007-06-12 PT PT07725977T patent/PT2040702E/pt unknown
- 2007-06-12 PL PL07725977T patent/PL2040702T3/pl unknown
- 2007-06-12 AT AT07725977T patent/ATE517621T1/de active
- 2007-06-12 CA CA2657335A patent/CA2657335C/en active Active
- 2007-07-13 AR ARP070103120A patent/AR061994A1/es unknown
-
2008
- 2008-12-30 IL IL196280A patent/IL196280A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CA2657335A1 (en) | 2008-01-17 |
| FR2903695A1 (fr) | 2008-01-18 |
| EP2040702B1 (en) | 2011-07-27 |
| PL2040702T3 (pl) | 2011-11-30 |
| JP2009542734A (ja) | 2009-12-03 |
| CA2657335C (en) | 2015-01-27 |
| ATE517621T1 (de) | 2011-08-15 |
| EP2040702A1 (en) | 2009-04-01 |
| US20090253764A1 (en) | 2009-10-08 |
| AU2007272082A1 (en) | 2008-01-17 |
| IL196280A (en) | 2013-02-28 |
| US8329738B2 (en) | 2012-12-11 |
| WO2008006432A1 (en) | 2008-01-17 |
| JP5237941B2 (ja) | 2013-07-17 |
| DK2040702T3 (da) | 2011-09-05 |
| IL196280A0 (en) | 2009-09-22 |
| FR2903695B1 (fr) | 2008-10-24 |
| ES2367852T3 (es) | 2011-11-10 |
| AU2007272082B2 (en) | 2012-05-24 |
| PT2040702E (pt) | 2011-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR061994A1 (es) | Uso de derivados de imidazol activadores de ampk, su proceso de preparacion y composiciones farmaceuticas que los comprenden | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| AR068538A1 (es) | Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido | |
| AR066583A1 (es) | Derivados de 3,3-espiroindolinona | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| CR10643A (es) | DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZOL[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA | |
| AR060591A1 (es) | Compuestos imidazo | |
| AR060590A1 (es) | Compuestos imidazo | |
| AR091790A1 (es) | Derivados de isoquinolin-1-ona y sus usos | |
| AR106472A1 (es) | Inhibidores de acc y usos de los mismos | |
| AR047456A1 (es) | Derivados de amidas, procesos para su preparacion y uso como insecticidas | |
| AR075635A1 (es) | N-alcoxiamidas de 6-(fenil sustituido)-4-aminopicolinatos y 2-(fenil sustituido)-6-amino-4-pirimidina carboxilatos, su uso como herbicidas selectivos para las cosechas y proceso de preparacion de dichos compuestos | |
| AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
| AR067886A1 (es) | Derivados de acido azabifenilaminobenzoico | |
| AR066954A1 (es) | Derivados de 7- alquinil-1,8- naftiridonas , su preparacion y su aplicacion en terapeutica | |
| ES2530943T3 (es) | Derivados de la cromenona con actividad antitumoral | |
| AR066107A1 (es) | Derivados de triazolopiridin - carboxamidas y triazolopirimidin-carboxamidas, su preparacion y su aplicacion en terapeutica como inhibidores de la enzimamonoacil glicerol lipasa y composiciones qu los contienen. | |
| ECSP10010473A (es) | Nuevos derivados de carbazol, inhibidores de hsp90, composiciones que los contienen y utilización | |
| AR075583A1 (es) | Derivados de isoxazol/o-piridina con eslabon etilo o etenilo | |
| BRPI0617880B8 (pt) | composto derivado de piridina substituído por heterociclo, composição farmacêutica, medicamento e agente antifúngico que compreende o dito composto e uso do mesmo para prevenir e/ou tratar infecção fúngica | |
| ECSP099682A (es) | Nuevos compuestos heterociclicos nitrogenados, su preparación y su utilización como medicamentos antibacterianos | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
| UY32801A (es) | Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR066604A1 (es) | Derivados de arilamida pirimidona, medicamentos que los contienen y usos terapeuticos para prevenir y/o tratar enfermedades neurodegenerativas fundamentalmente. | |
| ES2559854T3 (es) | Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |